DxDiscovery

DxDiscovery is a private, pre-revenue biotech company leveraging antibody discovery to create lateral flow diagnostics and therapeutic candidates for infectious diseases. Its core strategy involves identifying microbial biomarkers, generating monoclonal antibodies against them, and incorporating these into user-friendly, point-of-care tests similar to at-home COVID-19 tests. The company operates through academic and clinical partnerships to complement its internal R&D capabilities, aiming to address critical gaps in diagnostic sensitivity, specificity, and accessibility.

Integrated platform for discovering microbial biomarkers, generating high-affinity monoclonal antibodies against them, and incorporating antibodies into optimized immunoassays, with a focus on lateral flow format for point-of-care diagnostics.

Competes in the crowded rapid diagnostics space against large, established diagnostics firms (e.g., Abbott, QuidelOrtho) and numerous startups. Differentiation hinges on superior antibody performance, targeting specific disease niches with poor existing diagnostics, and a partnership-driven development model.